Zymeworks Reports Third Quarter 2026 Financial Results and Raises Full-Year Guidance

Zymeworks reported third-quarter 2026 revenue of $256.5 million, above the $227.4 million analyst consensus, and earnings per share of $2.28 versus expectations of $2.27. The company raised its 2026 revenue guidance to $337 million–$351 million and Adjusted EBITDA guidance to $176 million–$190 million. It completed its acquisition of Theravance Biopharma on September 23, a deal expected to lower annual operating expenses by $13 million–$15 million, and entered an exclusive global collaboration and license agreement with Roche for its ZW209 program in October.